Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials

Pharmacogenetics and biomarkers are becoming normalised as important technologies to improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed choices for targeted therapies. However, their wider clinical implementation has been limited by a lack of robust eviden...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Danielle, Hughes, Dyfrig, Pirmohamed, Munir, Jorgensen, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789450/
https://www.ncbi.nlm.nih.gov/pubmed/31480618
http://dx.doi.org/10.3390/jpm9030042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789450/
https://www.ncbi.nlm.nih.gov/pubmed/31480618
http://dx.doi.org/10.3390/jpm9030042

Ejemplares similares